Ustekinumab in the treatment of palmoplantar pustulosis

British Journal of Dermatology

Volumn 163, Issue 5, 2010, Pages 1116-1118

  Gerdes, S ^a   Franke, J ^a   Domm, S ^a   Mrowietz, U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

IL 12 23; P40 antagonist; Palmoplantar pustulosis (PPP); Treatment; Ustekinumab

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

ADULT; AGED; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOOT; HAND; HUMAN; HYPERTENSION; IMMOBILIZATION; LETTER; LOW DRUG DOSE; MONOTHERAPY; OBESITY; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULE; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; SMOKING; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOOT DERMATOSES; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PSORIASIS; SMOKING; TREATMENT OUTCOME;

EID: 78249281659     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09897.x     Document Type: Letter

References (7)

1. Marsland AM, Chalmers R, Hollis S, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006; 1: CD001433.
2. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339 -50.
3. Witowski J, Ksiazek K, Jorres A,. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004; 61: 567 -79.
4. Watanabe H, Kawaguchi M, Fujishima S, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009; 129: 650 -6.
5. Pelletier M, Maggi L, Micheletti A, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010; 115: 335 -43.
6. Roussel L, Houle F, Chan C, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010; 184: 4531 -7.
7. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665 -74.